Nyxoah Reports 365% Year-Over-Year Revenue Growth in Q3 2026
Nyxoah SA (NYXH) reported significant commercial momentum in its third quarter of 2026, with global net revenue reaching EUR 9.2 million, a 365% increase compared to the same period last year. This growth was driven largely by U.S. operations, which contributed EUR 6.7 million. The company is successfully transitioning from a research-oriented firm to a commercial entity, evidenced by an increase in trained surgeons and active accounts. Despite the strong revenue surge and improved gross margins of 63.1%, Nyxoah revised its full-year revenue guidance to between EUR 33 million and EUR 35 million to better align with historical adoption curves for new technology. The company is currently focusing on deepening market penetration in the U.S. through its sales force while pursuing label expansion via a PMA supplement for patients with complete concentric collapse.
Tickers: $NYXH
Topics: Financial Guidance Gross Margin Operating Loss Revenue Growth